SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Divi's Laboratories reports 17% rise in Q3 consolidated net profit

12 Feb 2024 Evaluate

Divi's Laboratories has reported results for third quarter ended December 31, 2023 (Q3FY24).

The company has reported 15.48% rise in its net profit at Rs 358 crore for the third quarter ended December 31, 2023 as compared to Rs 310 crore for the same quarter in the previous year. Total income of the company increased by 5.26% at Rs 1902 crore for Q3FY24 as compared Rs 1807 crore for corresponding quarter of the previous year. 

On consolidated basis, the company has reported 16.99% rise in net profit at Rs 358 crore for Q3FY24 as compared to Rs 306 crore for the same quarter in the previous year. Total income of the company increased by 7.08% at Rs 1950 crore for Q3FY24 as compared Rs 1821 crore for corresponding quarter of the previous year.

Divis Lab Share Price

6359.20 -19.55 (-0.31%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×